Related Experiment Videos
Continuous infusion of coagulation factors
1The National Hemophilia Center, Institute of Hematology and Blood Transfusion, University Hospital, Bratislava, Slovakia.
Summary
Continuous infusion (CI) of coagulation factors offers improved safety and efficacy for haemophilia A, B, and von Willebrand disease. This method maintains steady haemostatic levels, reducing concentrate consumption and costs compared to intermittent injections.
Area of Science:
- Hematology
- Pharmacology
Background:
- Continuous infusion (CI) of coagulation factor concentrates aims to maintain stable haemostatic levels.
- This approach prevents dangerous factor troughs and high peaks, enhancing safety and reducing concentrate usage.
- CI has been utilized since the early 1990s after addressing stability, contamination, and pharmacokinetic concerns.
Purpose of the Study:
- To evaluate the advantages of continuous infusion for coagulation factor replacement therapy.
- To demonstrate improved efficacy and safety margins in clinical settings requiring prolonged haemostatic level maintenance.
Main Methods:
- Administration of coagulation factors at a rate matching their elimination.
- Utilizing adequate minipumps for prolonged drug delivery.
- Clinical experience in haemophilia A, B, and von Willebrand disease.
Main Results:
- Continuous infusion maintains steady haemostatic factor levels, avoiding troughs and peaks.
- Proven advantages in various clinical settings requiring sustained haemostasis.
- Demonstrated reduction in treatment costs compared to intermittent injections.
Conclusions:
- Continuous infusion is an effective and safe method for managing haemophilia and von Willebrand disease.
- CI offers improved therapeutic outcomes and cost-effectiveness over traditional intermittent factor replacement.
- Further clinical experience validates CI as a superior mode of therapy for specific indications.